Quick answer: A Mediterranean dietary pattern is associated with 13% lower overall cancer risk in a meta-analysis of 83 studies (Schwingshackl 2017, International Journal of Cancer), while obesity — now the second leading preventable cause of cancer after tobacco — drives 13 cancer types including colorectal, breast, endometrial, and pancreatic cancers via insulin/IGF-1 signaling, chronic inflammation, and adipokine dysregulation. Functional oncology addresses the modifiable metabolic, inflammatory, and nutritional terrain that influences cancer initiation, progression, treatment tolerance, and recurrence risk.
The Terrain Theory: Why the Metabolic Environment Matters
The “seed and soil” metaphor for cancer — where the tumor is the seed and the host metabolic environment is the soil — dates to Stephen Paget’s 1889 observation in The Lancet and remains biologically accurate today. Genetic mutations are necessary but not sufficient for cancer progression: a metabolic environment characterized by hyperinsulinemia, chronic inflammation, oxidative stress, immune dysfunction, and gut microbiome dysbiosis provides the fertile terrain that allows mutated cells to proliferate, evade immune surveillance, and metastasize.
The International Agency for Research on Cancer (IARC) estimates that 30–40% of cancer cases are preventable through modifiable lifestyle factors. These include: physical inactivity (independent risk factor for 13 cancer types), obesity (13 cancer types via insulin/IGF-1/adipokine pathways), alcohol (7 cancer types including breast, colorectal, oral, esophageal, liver), tobacco, processed meat (Group 1 carcinogen — colorectal cancer, 18% relative risk increase per 50g/day — IARC 2015), and chronic infections (H. pylori → gastric, HPV → cervical/oropharyngeal, HBV/HCV → hepatocellular). Each represents a functional medicine intervention target.
Insulin, IGF-1, and the Cancer Proliferation Signal
Chronic hyperinsulinemia — the metabolic consequence of dietary carbohydrate excess and insulin resistance — drives cancer cell proliferation through multiple mechanisms. Insulin activates the PI3K/AKT/mTOR pathway, promoting cell survival and protein synthesis. Insulin stimulates IGF-1 (insulin-like growth factor-1) production from the liver; IGF-1 is among the most potent mitogenic signals in human biology, activating Ras-MAP kinase (proliferation) and PI3K/AKT (survival and anti-apoptosis) simultaneously. Elevated serum IGF-1 is associated with 30–50% higher risk of breast, colorectal, and prostate cancers in prospective cohort studies.
Metformin’s anti-cancer properties — reducing cancer incidence in type 2 diabetics by 25–35% across multiple retrospective analyses — are primarily mediated via AMPK activation (which inhibits mTOR), direct reduction of circulating insulin, and reduction of hepatic IGF-1 production. Berberine achieves equivalent AMPK activation through a distinct mechanism (inhibiting Complex I of the mitochondrial electron transport chain, raising AMP:ATP ratio) — with emerging evidence for anti-tumor properties in colorectal, breast, and gastric cancer cell lines and animal models.
Dietary Patterns and Insulin/IGF-1 Reduction
Intermittent fasting (IF) and caloric restriction consistently reduce serum insulin, IGF-1, and inflammatory cytokines. The CALERIE trial (Redman 2018, Cell Metabolism) demonstrated that 25% caloric restriction reduced IGF-1 by 11%, insulin by 24%, and CRP by 13% while reducing multiple cancer risk biomarkers in healthy adults. Time-restricted eating (TRE, eating within 8–10 hour window) reduces postprandial insulin spikes without requiring caloric restriction, making it more adherent for long-term practice.
The glycemic load of the diet independently predicts cancer risk: Gnagnarella et al. (2008, Nutrition, Metabolism and Cardiovascular Diseases) meta-analysis of 31 studies demonstrated that high glycemic load was associated with elevated colorectal, endometrial, and pancreatic cancer risk via insulin/IGF-1 upregulation. A dietary pattern minimizing refined carbohydrates and fructose, emphasizing non-starchy vegetables, legumes, and lean protein, reduces cancer-promoting insulin/IGF-1 signaling as the primary dietary anticancer mechanism.
Chronic Inflammation and Cancer: The NF-κB Axis
Chronic inflammation drives cancer progression through multiple mechanisms established by Hanahan and Weinberg in the “Hallmarks of Cancer” framework (2000, 2011, Cell): NF-κB activation promotes tumor survival (anti-apoptotic Bcl-2, BclXL upregulation), angiogenesis (VEGF induction), invasion (MMP-9), and immune evasion (PD-L1 upregulation). The NLRP3 inflammasome — activated by gut LPS, advanced glycation end products, saturated fatty acids, and oxidative stress — produces IL-1β and IL-18 that promote tumor microenvironment immunosuppression.
H. pylori infection causes chronic gastric mucosal inflammation via CagA-mediated NF-κB activation, directly driving gastric cancer in 1–3% of infected individuals over decades. Eradication of H. pylori reduces gastric cancer risk by 39% (Ford 2014, Cochrane Database). This is the paradigmatic example of functional oncology: identifying and eliminating the chronic inflammatory driver upstream of malignant transformation.
Anti-Inflammatory Dietary Patterns and Cancer Risk
Omega-3 fatty acids (EPA/DHA) generate specialized pro-resolving mediators (resolvins, protectins, maresins) that actively resolve inflammation rather than suppressing it. EPA competes with arachidonic acid for COX-2, producing 3-series prostaglandins (PGE3) with anti-inflammatory and anti-proliferative properties versus the cancer-promoting PGE2. Larsson et al. (2012, BMJ) meta-analysis demonstrated that higher fish/omega-3 intake was associated with 12% lower colorectal cancer risk per serving/week. For breast cancer, a meta-analysis of 21 prospective studies showed 14% lower risk in the highest versus lowest quintile of marine omega-3 intake.
Curcumin (BCM-95 bioavailable form, 500–1,000 mg/day) is the most extensively studied anti-inflammatory botanical agent in oncology: it inhibits NF-κB, AP-1, STAT3, and β-catenin signaling pathways that are constitutively active in many tumors. The Phase 2 trial by Carroll et al. (2011, Cancer Prevention Research) demonstrated that curcumin 4 g/day reduced rectal ACF (aberrant crypt foci — precancerous lesions) by 40% in smokers. Multiple Phase 1/2 trials confirm safety and tumor biomarker reduction across multiple cancer types at doses 2–8 g/day of standard curcumin (lower doses with enhanced-bioavailability preparations).
Vitamin D and Cancer Prevention: The Strongest Evidence
Vitamin D is the nutraceutical with the strongest cancer prevention evidence. Garland et al. (1989, The Lancet) first proposed the vitamin D-cancer hypothesis from geographic colon cancer distribution data; subsequent mechanistic studies confirmed VDR (vitamin D receptor) expression in virtually all cell types, with vitamin D activation inducing cell cycle arrest, differentiation, apoptosis, and inhibition of angiogenesis in cancer cells — direct anti-tumor mechanisms.
The VITAL trial (Manson 2019, NEJM) — the largest vitamin D RCT in cancer prevention — randomized 25,871 participants to vitamin D3 2,000 IU/day: no significant effect on total cancer incidence, but significant 25% reduction in cancer mortality (p=0.02). The VITAL Cancer subgroup analysis showed a 77% lower risk of metastatic or fatal cancer in participants with normal BMI taking vitamin D (Chandler 2020, JAMA Network Open). A prospective study by Lappe et al. (2017, JAMA) randomized 2,303 women to vitamin D3 2,000 IU + calcium: no statistically significant cancer incidence reduction, but the treatment arm maintained higher vitamin D levels and showed 35% lower cancer rates (not reaching significance due to higher-than-expected baseline levels in the placebo arm, attenuating the effect size).
Target 25-OH vitamin D >60 ng/mL for cancer risk reduction — substantially above the conventional sufficiency cutoff of 30 ng/mL. Serum levels of 60–80 ng/mL are associated with the lowest cancer incidence in prospective observational data (Garland 2016, PLOS ONE). Monitoring for hypercalcemia and hypercalciuria at doses >5,000 IU/day is appropriate clinical practice.
The Gut Microbiome and Cancer: Immunotherapy Response and Risk
The gut microbiome has emerged as a critical determinant of both cancer risk and cancer immunotherapy response — perhaps the most rapidly developing area in oncology research. Gut microbiome composition influences the systemic immune tone via SCFA-mediated regulatory T-cell programming and systemic dendritic cell activation: a diverse, butyrate-rich microbiome supports the cytotoxic T-cell responses that identify and eliminate mutated cells before they become clinically detectable tumors.
Vetizou et al. (2015, Science) and Sivan et al. (2015, Science) simultaneously published landmark studies showing that gut microbiome composition determined response to anti-CTLA4 (ipilimumab) and anti-PD-L1 checkpoint immunotherapy in mouse models — with specific Bifidobacterium and Bacteroides species associated with response versus resistance. Gopalakrishnan et al. (2018, Science) confirmed this in human melanoma patients: responders to anti-PD-1 (pembrolizumab) had higher gut microbiome diversity and specifically higher Faecalibacterium prausnitzii abundance versus non-responders. This finding has profound clinical implications: gut microbiome optimization may enhance immunotherapy efficacy.
Key Functional Oncology Nutrients and Phytochemicals
Sulforaphane: NRF2 Activation and Epigenetic Cancer Prevention
Sulforaphane (from broccoli sprouts — 30–100× more potent than mature broccoli) is the most comprehensively studied dietary cancer prevention compound. Its dual mechanism is uniquely valuable: NRF2 activation upregulates phase II detoxification enzymes (UDP-glucuronosyltransferases, glutathione S-transferases) that neutralize carcinogens before DNA damage occurs; simultaneously, sulforaphane inhibits histone deacetylases (HDAC inhibition), reactivating tumor suppressor genes silenced by epigenetic methylation. Singh et al. (2009, Carcinogenesis) demonstrated sulforaphane significantly inhibited breast cancer stem cell growth at clinically achievable concentrations. Egner et al. (2014, Cancer Prevention Research) showed broccoli sprout extract reduced urinary aflatoxin biomarkers by 67% in a high-risk Chinese population.
Lycopene and Prostate Cancer
Lycopene — the red carotenoid in tomatoes, watermelon, and grapefruit — accumulates specifically in prostate tissue and demonstrates anti-proliferative, anti-angiogenic, and antioxidant properties in prostate cancer cells. Kucuk et al. (2002, Cancer Epidemiology, Biomarkers & Prevention) conducted a randomized presurgical trial in localized prostate cancer: lycopene supplementation 30 mg/day for 3 weeks pre-prostatectomy significantly reduced tumor volume, PSA, and surgical margin positivity versus placebo. Meta-analysis of 26 studies (Chen 2013) confirmed inverse association between dietary lycopene and prostate cancer risk. Cooking tomatoes in olive oil (as in marinara sauce) increases lycopene bioavailability 4-fold.
Resveratrol, EGCG, and Quercetin
Resveratrol (trans-resveratrol from red wine, polygonum cuspidatum root — 100–500 mg/day as trans-resveratrol) activates SIRT1, inhibits NF-κB, and reduces IGF-1R signaling with demonstrated efficacy in colorectal cancer prevention biomarkers (Patel 2010, Cancer Prevention Research). EGCG (epigallocatechin gallate from green tea — 400–800 mg/day) inhibits HER2/neu and VEGF signaling, with epidemiological evidence for reduced breast cancer risk in Japanese cohort studies correlating with green tea consumption. Quercetin (500 mg/day with bromelain for enhanced absorption) inhibits PI3K/AKT, induces autophagy, and demonstrated Phase 2 evidence for familial adenomatous polyposis polyp reduction in combination with curcumin.
Supportive Oncology: Nutrition During Cancer Treatment
During active cancer treatment, functional medicine shifts focus to optimizing treatment tolerance, protecting healthy tissue, and supporting immune function — while avoiding interactions with chemotherapy or radiation that could reduce efficacy. Key evidence-based supportive interventions: high-protein intake (>1.5 g/kg/day, or >2.0 g/kg/day during chemotherapy to prevent sarcopenia), omega-3 supplementation for cachexia prevention (EPA 2 g/day shown to attenuate weight loss in advanced cancer — Fearon 2006, Gut), vitamin D optimization (low vitamin D at diagnosis predicts worse outcomes across multiple cancer types), and gut microbiome preservation through antibiotic-sparing strategies and probiotic supplementation.
Important cautions: antioxidant supplementation timing relative to radiation and certain chemotherapy regimens requires oncologist coordination — some regimens rely on ROS generation for tumor cell killing, where high-dose antioxidants could theoretically reduce efficacy (though this remains controversial in the clinical literature). The integrative oncology approach of the Society for Integrative Oncology (SIO) recommends specific supplements with established safety profiles during treatment while avoiding theoretical interactions with treatment-generated oxidative mechanisms.
Cancer Recurrence Prevention: The Modifiable Risk Terrain
Post-cancer functional medicine focuses on reducing the metabolic terrain that promotes recurrence: sustained insulin/IGF-1 reduction through dietary carbohydrate quality and exercise; chronic inflammation reduction via Mediterranean dietary pattern and omega-3; vitamin D optimization; gut microbiome diversity preservation; and sleep optimization (disrupted circadian biology is independently associated with cancer recurrence via NK cell and cytotoxic T-cell suppression). The Women’s Healthy Eating and Living (WHEL) study and multiple exercise intervention trials demonstrate that lifestyle optimization post-diagnosis significantly improves disease-free survival in breast cancer patients.
For patients in Southeast Michigan seeking functional medicine evaluation of cancer risk, metabolic optimization for cancer prevention, or supportive oncology protocols, Dr. Tom Biernacki and the team at The Private Practice offer evidence-based personalized assessment. This includes comprehensive metabolic cancer risk biomarker evaluation, nutritional optimization, and individualized protocols. Call (810) 206-1402 to schedule a consultation.